ViiV Healthcare is a step closer to getting approval for the first single-pill, two-drug HIV regimen on this side of the Atlantic after the European Medicines Agency's scientific committee granted a positive opinion to Juluca (dolutegravir/rilpivirine).
ViiV Two-Drug HIV Pill Juluca Close To Europe Okay
The likely EMA approval of Juluca challenges the traditional HIV treatment paradigm of a three-drug regimen, with the single tablet, two-drug regimen offering the same efficacy as well as reduced toxicity and greater convenience.
More from Anti-infective
More from Therapy Areas
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.